patient treatment cost pre-announce signific
oper upsid last week today releas full oper result see
upsid driven strong sequenti cost save patient cost per treatment
declin sequenti repres one largest sequenti cost declin
seen compani manag cite improv product
primari driver sequenti cost declin also note under-perform
vs intern expect outperform suggest cost per tx
somewher middl result calcimimet contribut
ebitda similar anticip similar benefit third quarter
although expect contribut declin materi fourth quarter
medicar catch lower acquisit cost categori estim
assum contribut ebitda
volum growth still weak preview compani last week non-acquir
treatment growth remain weak grow y/i vs estim today
call manag acknowledg industri growth slow somewhat
under-perform industri note post organ volum
growth qtr timelin recoveri growth provid although
manag impli slower growth least part self-inflict
suggest compani becom judici expand clinic case
increment growth may justifi increas cost california also
given exampl state compani significantli pare back denovo
facil open year due on-going union-driven threat disrupt davita
open new clinic state year vs typic base average
patients/cent estimate ca slowdown could account volum growth
rais estim follow out-performance rais
ebitda estim
ep estim increas
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight like risk/reward head
particularli given expect
sale dmg expect materi share
repo next year pro-forma dmg sale
share trade signific discount
histor trade rang
estim revis higher multipl
expand ebitda
commerci mix pressur increas drive mix
increment result revis
ebitda estim proce sale dmg
less expect result lower share repo
forward ebitda multipl contract
pro-forma sale
incom y/i q/q na na na na na na na patient bad incom y/i y/i expens incom y/i tax share barclay davita inc
patrick feeley steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli
indirectli relat specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
